Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

Similar articles for PubMed (Select 24095054)

1.

Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides.

Charles P, Bienvenu B, Bonnotte B, Gobert P, Godmer P, Hachulla É, Hamidou M, Harlé JR, Karras A, Lega JC, Le Quellec A, Mahr AD, Mouthon L, Papo T, Puéchal X, Pugnet G, Samson M, Sibilia J, Terrier B, Vandergheynst F, Guillevin L; French Vasculitis Study Group.

Presse Med. 2013 Oct;42(10):1317-30. doi: 10.1016/j.lpm.2013.08.003. Epub 2013 Oct 2.

PMID:
24095054
2.

Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.

Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, Quémeneur T, Blanchard-Delaunay C, Godmer P, Puéchal X, Carron PL, Hatron PY, Limal N, Hamidou M, Ducret M, Daugas E, Papo T, Bonnotte B, Mahr A, Ravaud P, Mouthon L; French Vasculitis Study Group.

N Engl J Med. 2014 Nov 6;371(19):1771-80. doi: 10.1056/NEJMoa1404231.

3.

[Renal disease in ANCA-associated vasculitis].

Vanhille P, Vrigneaud L, Quéméneur T.

Presse Med. 2012 Mar;41(3 Pt 1):247-53. doi: 10.1016/j.lpm.2011.11.009. Epub 2012 Jan 21. Review. French.

PMID:
22265953
4.

S3. Rituximab for ANCA-associated vasculitides: the French experience.

Charles P, Guillevin L.

Presse Med. 2013 Apr;42(4 Pt 2):534-6. doi: 10.1016/j.lpm.2013.01.050. Epub 2013 Feb 26. Review. No abstract available.

PMID:
23453207
5.

Rituximab for ANCA-associated vasculitides.

Guillevin L.

Clin Exp Rheumatol. 2014 May-Jun;32(3 Suppl 82):S118-21. Epub 2014 May 16. Review.

PMID:
24854382
6.

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.

Guerry MJ, Brogan P, Bruce IN, D'Cruz DP, Harper L, Luqmani R, Pusey CD, Salama AD, Scott DG, Savage CO, Watts RA, Jayne DR.

Rheumatology (Oxford). 2012 Apr;51(4):634-43. doi: 10.1093/rheumatology/ker150. Epub 2011 May 25.

7.

[Rituximab for the treatment of ANCA associated vasculitis: the future today?].

Alba MA, Flores-Suárez LF.

Reumatol Clin. 2011 Dec;7 Suppl 3:S41-6. doi: 10.1016/j.reuma.2011.10.006. Epub 2011 Nov 23. Review. Spanish.

8.

[Maintainance treatment of anti-neutrophil cytoplasm associated antibodies (ANCA)].

Dábague Guzmán J, Pedroza Granados J, Zúñiga Varga J.

Reumatol Clin. 2011 Dec;7 Suppl 3:S37-40. doi: 10.1016/j.reuma.2011.10.005. Epub 2011 Nov 25. Review. Spanish.

9.

[The role of rituximab in the treatment of ANCA-associated systemic vasculitis].

Roccatello D, Vangelista A, Pani A.

G Ital Nefrol. 2011 Sep-Oct;28(5):474-88. Review. Italian.

PMID:
22028261
10.

Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis.

Niles J.

Clin Exp Immunol. 2011 May;164 Suppl 1:27-30. doi: 10.1111/j.1365-2249.2011.04363.x. Review.

11.

Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: update.

Santana AN, Woronik V, Halpern AS, Barbas CS.

J Bras Pneumol. 2011 Nov-Dec;37(6):809-16. Review. English, Portuguese.

12.

Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.

Charles P, Néel A, Tieulié N, Hot A, Pugnet G, Decaux O, Marie I, Khellaf M, Kahn JE, Karras A, Ziza JM, Deligny C, Tchérakian C, Guillevin L; French Vasculitis Study Group.

Rheumatology (Oxford). 2014 Mar;53(3):532-9. doi: 10.1093/rheumatology/ket381. Epub 2013 Nov 26.

PMID:
24282319
13.

[Diagnosis and management of small vessel vasculitides].

Pettersson T, Karjalainen A.

Duodecim. 2010;126(12):1496-507. Review. Finnish.

PMID:
20617753
14.

Treatment of ANCA-associated vasculitis: new therapies and a look at old entities.

Zand L, Specks U, Sethi S, Fervenza FC.

Adv Chronic Kidney Dis. 2014 Mar;21(2):182-93. doi: 10.1053/j.ackd.2014.01.009. Review.

PMID:
24602467
15.

Treatment of antineutrophil cytoplasmic antibody-associated vasculitis.

Rich EN, Brown KK.

Curr Opin Pulm Med. 2012 Sep;18(5):447-54. doi: 10.1097/MCP.0b013e32835701d6. Review.

PMID:
22854508
16.

Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.

Schönermarck U, Rau S, Fischereder M.

N Engl J Med. 2010 Nov 18;363(21):2072; author reply 2073-4. doi: 10.1056/NEJMc1009101#SA1. No abstract available.

PMID:
21083401
17.

Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.

Hebert LA, Ardoin S, Shim RL.

N Engl J Med. 2010 Nov 18;363(21):2072-3; author reply 2073-4. doi: 10.1056/NEJMc1009101#SA3. No abstract available.

PMID:
21083399
18.

Rituximab for rescue and maintenance therapy in rapidly progressive life-threatening antineutrophil cytoplasmic autoantibody-associated systemic vasculitis.

José RJ, Chrysochou C, Shurrab AE, New D, Wood GN.

Scand J Urol Nephrol. 2010 Dec;44(6):459-62. doi: 10.3109/00365599.2010.504193. Epub 2010 Jul 20.

PMID:
20645677
19.

Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.

Bunch DO, McGregor JG, Khandoobhai NB, Aybar LT, Burkart ME, Hu Y, Hogan SL, Poulton CJ, Berg EA, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2013 Mar;8(3):382-91. doi: 10.2215/CJN.03950412. Epub 2013 Jan 4.

20.

[Systemic vasculitides: novel nomenclature and novel therapeutic approaches].

Allali D, Chizzolini C.

Rev Med Suisse. 2014 Apr 16;10(426):854-8. French.

PMID:
24834643
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk